Our experimental results show that Hyp content, abnormalities of serum biochemistry and the hepatic expressions of CK19 and α-SMA in CLD mice are significantly alleviated in cycloastragenol and astragaloside I treatment groups. This evidence concerns the gene ACTA1 and congenital secretory chloride diarrhea 1.